|
|
|
|
| LEADER |
04196nma a2201285 u 4500 |
| 001 |
EB002048315 |
| 003 |
EBX01000000000000001191981 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
220822 ||| eng |
| 020 |
|
|
|a 9783036525730
|
| 020 |
|
|
|a books978-3-0365-2572-3
|
| 020 |
|
|
|a 9783036525723
|
| 100 |
1 |
|
|a Subramanian, Subree
|
| 245 |
0 |
0 |
|a Cancer Immunology
|h Elektronische Ressource
|
| 260 |
|
|
|a Basel, Switzerland
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2021
|
| 300 |
|
|
|a 1 electronic resource (316 p.)
|
| 653 |
|
|
|a tryptophan 2,3 dioxygenase 2
|
| 653 |
|
|
|a IL15
|
| 653 |
|
|
|a treatment free interval
|
| 653 |
|
|
|a immune evasion
|
| 653 |
|
|
|a CD19-CAR-T
|
| 653 |
|
|
|a resistance
|
| 653 |
|
|
|a organ transplantation
|
| 653 |
|
|
|a interferon
|
| 653 |
|
|
|a sortase A
|
| 653 |
|
|
|a combination immunotherapy
|
| 653 |
|
|
|a antigen-presenting cells
|
| 653 |
|
|
|a anti-CTLA-4
|
| 653 |
|
|
|a IFN-γ
|
| 653 |
|
|
|a RNA methylation
|
| 653 |
|
|
|a bispecific antibody
|
| 653 |
|
|
|a Fab
|
| 653 |
|
|
|a n/a
|
| 653 |
|
|
|a tumor microenvironment
|
| 653 |
|
|
|a m6A
|
| 653 |
|
|
|a IL-7
|
| 653 |
|
|
|a systemic treatment
|
| 653 |
|
|
|a NKG2D
|
| 653 |
|
|
|a cancer vaccine
|
| 653 |
|
|
|a kynurenine pathway
|
| 653 |
|
|
|a Medicine / bicssc
|
| 653 |
|
|
|a epidemiologic studies
|
| 653 |
|
|
|a primary liver cancer
|
| 653 |
|
|
|a cell therapy
|
| 653 |
|
|
|a carcinoma
|
| 653 |
|
|
|a immunosuppression
|
| 653 |
|
|
|a KIR
|
| 653 |
|
|
|a antibody-dependent cellular cytotoxicity (ADCC)
|
| 653 |
|
|
|a chemo-enzymatic approach
|
| 653 |
|
|
|a immunotherapy
|
| 653 |
|
|
|a NK cells
|
| 653 |
|
|
|a T-cell priming
|
| 653 |
|
|
|a inhibitory CAR
|
| 653 |
|
|
|a multi-state modelling
|
| 653 |
|
|
|a PD-L1
|
| 653 |
|
|
|a Atypical Chemokine Receptor 4 (ACKR4)
|
| 653 |
|
|
|a CD28
|
| 653 |
|
|
|a immune checkpoints
|
| 653 |
|
|
|a TIL
|
| 653 |
|
|
|a prostate cancer
|
| 653 |
|
|
|a BAP1
|
| 653 |
|
|
|a DNA methylation
|
| 653 |
|
|
|a B cell aplasia
|
| 653 |
|
|
|a CTLA-4
|
| 653 |
|
|
|a colorectal cancer
|
| 653 |
|
|
|a immune checkpoint inhibitors
|
| 653 |
|
|
|a MICA/B mAb
|
| 653 |
|
|
|a cancer
|
| 653 |
|
|
|a IDO inhibitor
|
| 653 |
|
|
|a S-adenosylmethionine (SAM)
|
| 653 |
|
|
|a colon cancer
|
| 653 |
|
|
|a triple negative breast cancer
|
| 653 |
|
|
|a melanoma
|
| 653 |
|
|
|a dendritic cells
|
| 653 |
|
|
|a tumor-infiltrating lymphocytes
|
| 653 |
|
|
|a PD-1
|
| 653 |
|
|
|a adaptive immunity
|
| 653 |
|
|
|a immune checkpoint blockade
|
| 653 |
|
|
|a chemotherapy
|
| 653 |
|
|
|a anti-CD20 antibody
|
| 653 |
|
|
|a T cells
|
| 653 |
|
|
|a anti-PD-1
|
| 653 |
|
|
|a osteoclasts
|
| 653 |
|
|
|a uveal
|
| 653 |
|
|
|a immunomodulation
|
| 653 |
|
|
|a cytotoxicity
|
| 653 |
|
|
|a cancer stem cells (CSCs)
|
| 653 |
|
|
|a CAR T
|
| 653 |
|
|
|a classical and endemic Kaposi Sarcoma
|
| 653 |
|
|
|a indoleamine 2,3 dioxygenase 1
|
| 653 |
|
|
|a Treg cells
|
| 653 |
|
|
|a BiFab
|
| 653 |
|
|
|a TCR diversity
|
| 653 |
|
|
|a antigen presenting cells
|
| 653 |
|
|
|a innate immunity
|
| 653 |
|
|
|a differentiation
|
| 700 |
1 |
|
|a Zhao, Xianda
|
| 700 |
1 |
|
|a Subramanian, Subree
|
| 700 |
1 |
|
|a Zhao, Xianda
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
| 028 |
5 |
0 |
|a 10.3390/books978-3-0365-2572-3
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/77108
|z DOAB: description of the publication
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/4727
|7 0
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 363
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 580
|
| 520 |
|
|
|a The past decade has seen immunotherapy rise to the forefront of cancer treatment. This Special Issue of Cancers aims to elaborate on the latest developments, cutting-edge technologies, and prospects in cancer immunology and immunotherapy. Seventeen exceptional studies, including original contributions and review articles, written by international scientists and physicians, primarily concerning the fields of tumor biology, cancer immunology, therapeutics, and drug development, comprise the main body of this Special Issue.
|